See releated articles, pp 2653, 2654, 2665, 2671
A trial fibrillation (AF) is a common cause of cardioembolism and ischemic stroke (IS). Long-term oral anticoagulation (OAC) is the mainstay therapy for IS prevention in patients with AF. However, uncertainties exist about the safety of OAC in AF patients with coexisting cerebral microbleeds (CMBs). Several studies suggest that individuals with CMBs seem to be at increased risk for future stroke, in particular intracerebral hemorrhage (ICH). [1] [2] [3] [4] Also, the presence and number of CMBs seem to correlate with CHADS 2 and CHADS 2 -VASC scores (congestive heart failure/left ventricular systolic dysfunction, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA or thromboembolism, vascular disease), which are used to estimate IS risk in patients with AF. 5, 6 As a result, the detection of CMBs often raises the following host of questions and leads to a therapeutic dilemma.
1. Does the detection of CMBs in patients with AF imply high risk for ICH to offset any benefit from OAC? 2. Are predictive scales for the risk of bleeding or IS in patients with AF useful to stratify the risk/benefit and to aid with decision-making? 3. Does the burden and anatomic location of CMBs influence risks for future ICH? We will address these questions in this review and attempt to provide a pragmatic approach to the treatment of AF in patients with CMBs.
Cerebral Microbleeds
CMBs represent hemosiderin deposits caused by minor bleeding from microangiopathy. 7 They are often seen as small (usually <10 mm) hypointense dark areas of signal void on susceptibility-weighted or gradient-echo T2*-weighted magnetic resonance imaging (MRI). Overall, CMBs are associated with many of the classical risk factors for cerebrovascular disease 8 but are most commonly associated with cerebral amyloid angiopathy (CAA) and poorly controlled hypertension. The distribution of CMBs seems to depend on their underlying pathogenesis. CMBs in deep regions of the brain, such as the basal ganglia and brain stem, are often attributed to arteriosclerosis and hypertensive arteriopathy, whereas those in lobar cortical or subcortical locations are often attributed to CAA. 9, 10 Mixed CMBs in lobar and deep locations may be attributed to a combination of CAA and arteriosclerosis or hypertension alone. This distinction is important because it might have therapeutic implications on the use of anticoagulation in bleeding-prone conditions, such as CAA.
CMBs are often detected incidentally on brain MRI done for unrelated reasons, such as evaluation of stroke. The sensitivity and ability of MRI to detect CMBs varies depending on echo time, MRI spatial resolution, and field strength. 11 CMBs are common in the elderly and are increasingly detected in patients with stroke. In population studies, CMBs are detected in 21% of the general population and up to 40% of the elderly aged ≥80 years; 19% to 83% of patients with ICH; and ≤35% of patients with IS. 8, 9, 12, 13 
Prevalence of CMBs in Patients With AF
Like CMBs, AF is also common in older people. However, the prevalence and location of CMBs in nonstroke patients with AF or vice versa is not well known. In a study of 131 Japanese patients with AF and 112 controls without AF, patients with AF had a significantly higher prevalence of CMBs, but the exact incidence rate was not reported. 14 There is evidence to suggest that lobar CMBs may be more common than deep CMBs in patients with AF. In the Rotterdam study of communitydwelling individuals, lobar CMBs were detected on 1.5T MRI in ≤25% elderly individuals who are presumably at risk for AF and stroke. 15 In another study using 3T MRI, CMBs were found more often in lobar areas than deep areas in a significant proportion of patients with IS and associated AF. 16 There is more data on the prevalence of CMBs in patients with AF presenting with stroke. A retrospective analysis of a prospective registry of 785 patients with IS or transient ischemic attacks reported that CMBs were detected in 24% of patients and that CMBs (predominantly in lobar locations) were more frequent in patients with AF (30% versus 22%). 17 Patients who were using an OAC were more likely to have CMBs (37% versus 23%) and abundant CMBs (>10) even after adjustment for age. 17 In another study which included 134 patients hospitalized with IS because of AF and had T2* MRI, the prevalence of CMBs was 27.6%. 6 In a study of 550 Asian patients with IS and AF who underwent 1T, 1.5T, or 3T MRI, the prevalence of CMBs was 31.5%. 5 Similar studies, however, have reported a much lower incidence of CMBs (6.8%) in patients with cardioembolic stroke because of AF. 18 The observed variability in the reported prevalence of CMBs in the above studies may be attributed, at least in part, to variability in the field strength of MRI used between these studies.
Relationship Between CMBs and ICH Risk
In a study of patients with IS because of AF, the presence of CMBs was independently associated with the development of ICH during a median follow-up of 3.1±1.6 years. 5 There might be an association between the number of CMBs and ICH risk. In 1 study, the odds ratio for future ICH increased from 1.8 (95% confidence interval [CI], 0.62-5.83) in patients with IS with ≥2 coexisting CMBs to 2.8 (95% CI, 0.80-9.93) with ≥5 CMBs, and 5.5 (95% CI, 1.46-20.77) with ≥10 CMBs. 19 In another study, patients using antiplatelet therapy who had >5 CMBs were at the highest risk for ICH compared with those with zero or <5 CMBs. 20 There is also evidence that patients with AF presenting with ICH tend to have a higher number of CMBs than their counterparts presenting with IS, suggesting that increased burden of CMBs may be related to the risk of ICH. In a retrospective cross-sectional study of 170 patients with stroke and AF (91% with IS and 9% with ICH), the prevalence of any CMBs was 49% (lobar in 94%; IS 48% and ICH 56%); multiple CMBs ≥2 was 30% (IS 29% and ICH 44%). 19 Sixty-nine percent of patients presenting with ICH versus 30% of those with IS were anticoagulated at the time of index event, and prior OAC use was more common among patients with ICH with multiple CMBs than those with single or no CMBs. 19 The risk of ICH in patients with multiple lobar CMBs can be particularly high. In a study of 63 patients with multiple incidental lobar CMBs (median, 10), the incidence rate of ICH during a mean follow-up of 5.3±3.8 years was 5 per 100 person years.
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Relationship Between Antithrombotic Therapy, CMBs, and ICH Risk
The reported overall risk for ICH in patients with AF taking warfarin varies from 0.1% to >2.5% per year. [22] [23] [24] This risk of ICH is lower in patients taking non-vitamin K-oral anticoagulants (NOACs). 25 In the AVERROES trial (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment), the risk of intracranial hemorrhage was similar in patients with AF treated with aspirin or apixaban. 26 Other studies provide indirect evidence to suggest that the presence of CMBs, in particular those located in lobar regions, might increase these risks. A single-center study that compared 63 patients with incidentally found CMBs and 316 with CAArelated ICH reported that the incidence of ICH in CMBs-only patients was not different from patients presenting with ICH during a mean follow-up of 5.3±3.8 years and that warfarin use and increasing age were independent predictors of future ICH among CMBs-only patients after adjustment for other variables. 21 In a pooled analysis of 1460 patients with ICH and 3817 with IS, case-case comparisons showed that CMBs were more common in warfarin-related than spontaneous ICH (odds ratio, 2.7; 95% CI, 1.6-4.4). 27 However, most of the included studies were retrospective in nature with limited prospective datasets. In a small, cross-sectional case-control study of 24 warfarin-related patients with ICH and randomly selected 48 warfarin-treated patients with no history of ICH, the presence of CMBs conferred >8-fold increase in the risk of warfarin-associated ICH, and the number and location of CMBs were also linked to ICH risk. 28 There is also evidence linking warfarin use to the development of CMBs. A recent prospective MRI study in 69 patients with AF in Japan reported that warfarin use was independently associated with the development of new CMBs (hazard ratio, 10.75; 95% CI, 1.22-94.99; P=0.03) during a 1-year followup period. 29 Interestingly, CMBs did not develop in any of the patients treated with direct/novel oral anticoagulant or antiplatelet therapy alone.
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Summary and Limitations of Current Knowledge
The aforementioned discussion suggests that the presence of CMBs is associated with increased risk for future stroke of any type; their presence in lobar locations is often indicative of CAA and, therefore, increased risk for ICH and that antithrombotic therapy, in particular warfarin, might aggravate the risk for ICH in patients with CMBs. However, supportive evidence from prospective longitudinal studies and clinical trials is yet to be available. The implications of racial and ethnic differences in regards to the prevalence and prognosis of CMBs are also understudied. In a meta-analysis of CMBs in patients with IS, the risk of ICH was 8-fold higher among those with versus those without CMBs. However, the association was much stronger for Asian compared with Western populations. More study is needed. There is also considerable heterogeneity in the literature, which is attributed in large part to the differences in MRI magnet strength and T2*-weighted imaging techniques (susceptibility-weighted versus gradient-echo). It is also important to point out that the underlying pathophysiology of strictly lobar CMBs in patients with AF is yet to be ascertained. Although strictly lobar CMBs are often attributed to CAA, there is no direct histopathologic evidence to confirm the underlying pathogenesis of lobar CMBs in patients with AF. Therefore, lobar CMBs in patients with AF might be associated with other conditions, which have lower risk for ICH with anticoagulant use, such as, white matter disease, antithrombotic use, or hypertension. This uncertainty requires further study.
It is likely that CMBs in a subgroup of yet-to-be-fully identified patients with AF can tip the risk/benefit balance away from OAC. However, there is paucity of studies clearly addressing the balance of future IS versus ICH in AF patients with CMBs. Several prospective multicenter studies, such as the CROMIS 2 (clinical relevance of microbleeds in stroke; https://clinicaltrials.gov/ct2/show/NCT02513316), intracerebral hemorrhage because of oral anticoagulants: prediction of the risk by MRI (HERO [Hirulog Early Reperfusion/Occlusion Trial]; https://clinicaltrials.gov/ct2/show/NCT02238470), and CMB-NOW (CMBs during NOACs or Warfarin therapy in nonvalvular atrial fibrillation patients with acute IS; https:// clinicaltrials.gov/ct2/show/NCT02356432) are ongoing. The completion and results from these studies together with evolving data from the recently established microbleeds international collaborative network and meta-microbleeds consortium 30, 31 should improve our understanding of the prognostic implications of CMBs overall and in patients with AF and to provide evidence-supported management strategies.
Because of the lack of clear evidence from randomized and prospective long-term longitudinal studies, uncertainties
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continue as to how best to address the preceding and following questions. It seems logical that the first step in the evaluation of patients with suspected CMBs on MRI is to ensure that the observed abnormalities truly represent CMBs and not other mimics, such as calcium or iron deposits or blood vessels seen on cross-sections.
Should MRI Be Used to Screen for CMBs Before Initiation of Antithrombotic Therapy?
Fisher 32 proposed an algorithm that incorporates MRI screening into the anticoagulation decision-making for patients with AF based on age ≥60 and presence and location (cortical/ subcortical) of CMBs. 32 He proposed that patients with AF ≥60 years of age should undergo MRI screening before initiating OAC. He recommended initiating anticoagulation in patients in whom MRI shows no cortical CMBs or <5 subcortical CMBs. In patients with any cortical CMBs or ≥5 subcortical CMBs, he recommended neurology consultation and avoiding warfarin in favor of NOACs if anticoagulation is contemplated. Furthermore, he recommended repeating MRI in patients who develop neurological changes during anticoagulation and discontinuing anticoagulation if the repeat MRI shows progression of CMBs. However, the validity of this approach has been questioned by others. Although these scoring systems seem to be helpful in predicting the overall bleeding risks, they do not incorporate the presence of CMBs and are of limited value in regards to assessing the risk of ICH alone. 19 The anatomic location of CMBs might be more relevant for risk stratification in combination with the use of Boston criteria and other imaging markers, such as superficial siderosis to diagnose probable or possible CAA, which could imply higher risk for ICH with anticoagulation. 35 In this regard, there is a side debate as to whether apolipoprotein E genotyping should be considered in patients with lobar CMBs to diagnose CAA because genotyping alone does not accurately identify patients with CAA. 36 The recent American Heart Association/American Stroke Association scientific statement on the prevention of stroke in patients with silent cerebrovascular disease 35 attempted to address several of the preceding uncertainties. It concluded that it is reasonable to provide anticoagulation or antiplatelet therapy to patients with CMBs when there is an indication such as AF and that MRI screening for CMBs before initiating therapy is not recommended; direct/novel oral anticoagulant is preferred compared with warfarin; and that percutaneous closure of the left atrial appendage (LAA) could be considered as an alternative.
Treatment Options in AF Patients With CMBs and a High Risk of ICH
Patients with AF need to be anticoagulated. In the large randomized trials comparing NOACs with warfarin for stroke prevention in AF, brain imaging was not performed in a systematic way to identify patients with an increased risk of ICH, for example, CMBs or small vessel disease. In addition, we are not aware of a study that identified a critical number of microbleeds which would result in a significantly higher bleeding risk in anticoagulated patients. Therefore, we would support anticoagulation in most patients diagnosed with CMBs and AF. Anticoagulation should be performed with NOACs instead of vitamin K antagonists due the significantly decreased risk of intracerebral bleeding. 25 We would also recommend against the concomitant use of aspirin. We encourage informing the patients and their providers about the gaps in our existing knowledge and engaging in a thorough discussion of the potential benefits versus risks. We would, however, discourage the use of anticoagulants in the following situations:
• patients with a history of lobar ICH (or superficial siderosis) and multiple cortical CMBs (the threshold number is not known at present)
• patients in whom the family history (ICH in middle age, early onset of dementia) and MRI indicate CAA.
• patients on dual antiplatelet therapy after acute coronary syndrome or percutaneuos coronary intervention and multiple lobar CMBs.
LAA Occlusion
According to recent guidelines, AF patients with long-term contraindications for OAC should be considered for occlusion of the LAA. 37 The randomized trials investigating LAA occlusion unfortunately did not include this particular population of patients. 38, 39 Patients undergoing LAA occlusion need to be able to tolerate dual antiplatelet therapy for ≈3 months after the procedure. Whether this treatment phase is associated with an increased risk of ICH in patients with CMBs is not known at present.
Ongoing Studies
There are 3 ongoing studies comparing NOACs with aspirin in patients with embolic stroke of undetermined source. In a subset of these patients, brain imaging with MRI is done at baseline and at the end of the study. After the conclusion of the studies, we will have more information about the location and number of microbleeds and the risk of intracerebral bleeding in patients on NOACs or aspirin.
Conclusions
In summary, more study is needed to ascertain how best to treat AF in patients with CMBs and to determine the characteristics of patients in whom OAC should be offered or avoided. Based on currently available evidence, it is not unreasonable to use OAC in most AF patients with CMBs. Several ongoing studies should provide a more definite guidance in the near future.
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